VSBC VITASPRING BIOMEDICAL CO. LTD.
Services-Commercial Physical & Biological Research · OTC · SEC CIK 1697884 · Fiscal year ends 01/31
Financial factors as of 2026-07-31 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY14.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-2,861.9%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets31,554.8%
Debt / equity—
Current ratio0.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.02x
Accruals ratio-2,928.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-07-31 | 2027Q12026-04-30 | 2026Q4*2026-01-31 | 2026Q32025-10-31 | 2026Q22025-07-31 | 2026Q12025-04-30 | 2025Q4*2025-01-31 | 2025Q32024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A expense | $5,830 | $75,844 | $81,464 | $135,733 | $6,054 | $69,147 | $48,129 | $117,927 |
| Operating income | -$161,817 | -$75,844 | -$81,464 | -$135,733 | -$99,067 | -$69,147 | -$48,129 | -$117,927 |
| Pretax income | -$155,817 | -$75,844 | -$81,464 | -$135,733 | -$99,067 | -$69,147 | -$48,129 | -$117,927 |
| Income tax | $0 | $0 | $0 | $6,785 | $11,778 | $11,394 | $95,008 | $78,365 |
| Net income | -$155,817 | -$75,844 | -$81,464 | -$142,518 | -$110,845 | -$80,541 | -$143,137 | -$196,292 |
| EBITDA | -$160,157 | -$73,355 | -$78,975 | -$133,244 | -$96,577 | -$66,658 | -$45,640 | -$115,438 |
| EPS (diluted) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Weighted avg. shares (diluted) | 207.03M | 207.03M | — | 207.03M | 207.03M | 207.03M | — | 207.03M |
| Balance sheet | ||||||||
| Cash & equivalents | $13,367 | $8,167 | $2,084 | $0 | $799 | $0 | $272 | $2,062 |
| Receivables | — | — | — | — | — | — | $0 | $0 |
| Current assets | $14,822 | $9,772 | $10,527 | $9,827 | $7,893 | $295 | $272 | $41,787 |
| PP&E, net | $0 | $1,660 | $4,149 | $6,638 | $9,127 | $11,617 | $14,106 | $16,595 |
| Total assets | $14,822 | $11,432 | $14,676 | $16,465 | $17,020 | $11,912 | $14,378 | $58,382 |
| Current liabilities | $2.27M | $4.52M | $4.45M | $4.37M | $4.22M | $4.11M | $4.03M | $3.93M |
| Total liabilities | $4.68M | $4.52M | $4.45M | $4.37M | $4.22M | $4.11M | $4.03M | $3.93M |
| Shareholders' equity | -$4.66M | -$4.51M | -$4.43M | -$4.35M | -$4.21M | -$4.10M | -$4.02M | -$3.87M |
| Shares outstanding | 207.03M | 207.03M | 207.03M | 207.03M | 207.03M | 207.03M | 207.03M | — |
| Cash flow statement | ||||||||
| Operating cash flow | $5,200 | $6,083 | $124 | -$839 | -$1,186 | -$787 | -$1,790 | -$6,441 |
| Financing cash flow | $0 | $0 | $0 | $2,000 | $1,985 | $515 | $0 | $2,978 |
| Depreciation & amortization | $1,660 | $2,489 | $2,489 | $2,489 | $2,490 | $2,489 | $2,489 | $2,489 |
| Stock-based compensation | — | — | $0 | $0 | $0 | $0 | $0 | $27,478 |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.